Original Biomedicals Co Ltd

Original Biomedicals Co Ltd

TTPEX:6483
13.30
TWD
-0.50
(-3.62%)
935.31MMarket Cap
Original Biomedicals Co Ltd
TPEX:6483
(Taipei Exchange)

Recent

price

13.30

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2022
2023
2024
2025
TTM
TWD
- -
- -
- -
0.57
- -
- -
- -
- -
0.01
- -
Revenue per Share
- -
-1.3
-8.12
-4.99
-4.69
-0.86
-1.21
-1.14
-1.53
- -
Basic EPS, GAAP
- -
-1.61
-9.67
-5.56
-5.2
-0.66
-0.56
-1.3
-1.46
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.4
0.85
6.12
21.09
14.53
1.47
5.06
3.87
2.37
1.66
Book Value per Share
0.4
0.85
6.12
21.09
14.53
1.47
5.06
3.87
2.37
1.65
Tangible Book Value per Share
13
10
3
17
24
47
49
66
66
67
Basic Weighted Avg Shares
- -
- -
- -
10
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
-906.06
- -
-37,547.66
-137,818.6
- -
-27,453.02
- -
Operating Margin (%)
- -
1
1
4
9
8
9
8
9
- -
Depreciation Expense
- -
-13
-22
-83
-114
-40
-60
-75
-102
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
-869.76
- -
-37,642.06
-138,746.51
- -
-26,643.04
- -
Profit Margin (%)
3
5
70
481
306
49
312
242
147
99
Working Capital
- -
- -
- -
- -
- -
16
12
7
7
4
LT Debt
5
11
81
517
343
69
327
255
158
111
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-158.16
-48.72
-27.72
-26.62
-19.54
-30.15
-25.78
-49.15
- -
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
5
4
5
LT Borrowings
- -
- -
- -
LT Finance Leases
5
7
4
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
66
67
67
Market Capitalization
899
922
935

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
214
164
116
Cash, Cash Equivalents & STI
198
144
71
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
16
17
17
Payables & Accruals
- -
- -
- -
ST Debt
5
4
5
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
39.73%
-38.16%
Free Cash Flow
- -
34.73%
12.81%
Net Income, GAAP
- -
16.51%
35.35%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-1.14
2025
- -
- -
-1.53
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Business
Original BioMedicals Co., Ltd. is a biotechnology firm dedicated to advancing therapeutic solutions for critical medical demands, particularly by enhancing existing drug compounds and developing innovative delivery systems. Its pipeline includes Radprotect, an early-stage candidate engineered to shield against radiation exposure. Also under development is CCM-Ami, designed to safeguard healthy tissues from the harmful impacts of chemotherapy and radiation treatments, and GLP-1 CCM for managing type 2 diabetes. Established in 2011, the company operates from its headquarters in Taipei, Taiwan.